Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
University of Chicago Medical Center, Chicago, Illinois, United States
Department of Hematology, Nanfang Hospital, Guangzhou, Guangdong, China
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
Tanvex Investigational Site 4002, Viña Del Mar, Chile
Tanvex Investigational Site 1007, Babruysk, Mogilev Region, Belarus
Tanvex Investigational Site 1008, Lesnoy, Minsk Region, Belarus
Levine Cancer Institute, Charlotte, North Carolina, United States
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.